Topical pan-JAK inhibitor
Delgocitinib
Brand names: Anzupgo
Adult dose
Dose: Apply thin layer BD to affected area
Route: Topical
Frequency: BD
Clinical pearls
- Chronic hand eczema in adults — NICE TA evaluation
- BAD eczema guidance
- Topical formulation minimises systemic JAK exposure (vs oral JAK inhibitors)
Contraindications
- Active local infection
- Hypersensitivity
Side effects
- Local irritation
- Folliculitis
- Herpes simplex / zoster reactivation (theoretical)
- Application-site burning
Monitoring
- Skin response
- Local infection signs
Reference: BNF; NICE TA evaluation; BAD; SmPC; https://bnf.nice.org.uk/drugs/delgocitinib/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD